Business Description
Polaris AI Pharma Corp
ISIN : KR7041910001
Description
Financial Strength
10/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 75.46 | |||||
Equity-to-Asset | 0.95 | |||||
Debt-to-EBITDA | 0.17 | |||||
Interest Coverage | 71.68 | |||||
Piotroski F-Score | 6/9 | |||||
Altman Z-Score | 9.15 | |||||
Beneish M-Score | -2.84 | |||||
WACC vs ROIC |
Growth Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 1.5 | |||||
3-Year EBITDA Growth Rate | -32.4 | |||||
3-Year EPS without NRI Growth Rate | -4.2 | |||||
3-Year FCF Growth Rate | 15.8 | |||||
3-Year Book Growth Rate | -0.2 |
Momentum Rank
8/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 60.16 | |||||
9-Day RSI | 52.78 | |||||
14-Day RSI | 47.32 | |||||
6-1 Month Momentum % | -28.03 | |||||
12-1 Month Momentum % | -1.83 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 15.26 | |||||
Quick Ratio | 11.18 | |||||
Cash Ratio | 7.91 | |||||
Days Inventory | 171.34 | |||||
Days Sales Outstanding | 91.21 | |||||
Days Payable | 17.28 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 1.71 | |||||
Dividend Payout Ratio | 0.65 | |||||
Forward Dividend Yield % | 1.71 | |||||
5-Year Yield-on-Cost % | 2.8 | |||||
Shareholder Yield % | 1.78 |
Profitability Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 21.79 | |||||
Operating Margin % | 3.28 | |||||
Net Margin % | 1.55 | |||||
FCF Margin % | -0.42 | |||||
ROE % | 0.78 | |||||
ROA % | 0.74 | |||||
ROIC % | 2.89 | |||||
ROC (Joel Greenblatt) % | 1.16 | |||||
ROCE % | 0.61 | |||||
Years of Profitability over Past 10-Year | 8 |
GF Value Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 85.88 | |||||
PE Ratio without NRI | 37.73 | |||||
PS Ratio | 1.17 | |||||
PB Ratio | 0.64 | |||||
Price-to-Tangible-Book | 0.64 | |||||
Price-to-Operating-Cash-Flow | 25.11 | |||||
EV-to-EBIT | 51.11 | |||||
EV-to-EBITDA | 11.89 | |||||
EV-to-Revenue | 0.62 | |||||
EV-to-FCF | -149.89 | |||||
Price-to-Projected-FCF | 0.7 | |||||
Price-to-Median-PS-Value | 0.5 | |||||
Price-to-Graham-Number | 1.04 | |||||
Price-to-Net-Current-Asset-Value | 1.07 | |||||
Price-to-Net-Cash | 2.26 | |||||
Earnings Yield (Greenblatt) % | 1.96 | |||||
FCF Yield % | -0.32 | |||||
Forward Rate of Return (Yacktman) % | -1.04 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Annualized Return % Â
Total Annual Return % Â
Polaris AI Pharma Corp Executives
DetailsAnalyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil â‚©) | 59,652.297 | ||
EPS (TTM) (â‚©) | 68 | ||
Beta | 1.11 | ||
Volatility % | 50.6 | ||
14-Day RSI | 47.32 | ||
14-Day ATR (â‚©) | 330.667886 | ||
20-Day SMA (â‚©) | 5721 | ||
12-1 Month Momentum % | -1.83 | ||
52-Week Range (â‚©) | 5010 - 12300 | ||
Shares Outstanding (Mil) | 13.28 |
Piotroski F-Score Details
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 6 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Polaris AI Pharma Corp Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Polaris AI Pharma Corp Stock Events
Event | Date | Price(â‚©) | ||
---|---|---|---|---|
No Event Data |
Polaris AI Pharma Corp Frequently Asked Questions
What is Polaris AI Pharma Corp(XKRX:041910)'s stock price today?
When is next earnings date of Polaris AI Pharma Corp(XKRX:041910)?
Does Polaris AI Pharma Corp(XKRX:041910) pay dividends? If so, how much?
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |